Hemangioendothelioma: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
'''Hemangioendotheliomas''' is a rare group of | '''Hemangioendotheliomas''' is a rare group of mesenchymal vascular neoplasms. Hemangioendotheliomas commonly present with an enlarging mass and have been reported in the [[head]] and [[neck]], [[lungs]], [[lymph nodes]], [[pleura]], [[retroperitoneum]], or [[stomach]]. Hemangioendotheliomas may be [[benign]] or [[malignant]], and tend to occur around medium to large venous structures. Hemangioendothelioma may be classified into 4 groups: epitheloid hemangioendothelioma (most common), kaposiform hemangioendothelioma, retiform hemangioendothelioma, and [[infantile hemangioendothelioma]]. The prevalence of hemangioendothelioma is approximately 1 per 100,000 individuals worldwide. | ||
The majority of patients with hemangioendothelioma are symptomatic at the time of diagnosis.<ref name="pmid3303234">{{cite journal |vauthors=Weiss SW, Ishak KG, Dail DH, Sweet DE, Enzinger FM |title=Epithelioid hemangioendothelioma and related lesions |journal=Semin Diagn Pathol |volume=3 |issue=4 |pages=259–87 |year=1986 |pmid=3303234 |doi= |url=}}</ref> Early clinical features of hemangioendothelioma are often unspecific | The majority of patients with hemangioendothelioma are symptomatic at the time of diagnosis.<ref name="pmid3303234">{{cite journal |vauthors=Weiss SW, Ishak KG, Dail DH, Sweet DE, Enzinger FM |title=Epithelioid hemangioendothelioma and related lesions |journal=Semin Diagn Pathol |volume=3 |issue=4 |pages=259–87 |year=1986 |pmid=3303234 |doi= |url=}}</ref> Early clinical features of hemangioendothelioma are often unspecific, such as: abdominal pain, mass, weight loss, or fatigue. On CT, characteristic findings of hepatic hemangioendothelioma, may include: multiple hypo-attenuating lesions in both hepatic lobes, coalesce to form larger confluent hypo-attenuating regions in a peripheral or subcapsular distribution, halo or target pattern of enhancement in larger lesions, subcapsular lesion (with capsular retraction), and located in a predominantly peripheral. Surgical [[resection]], [[radiotherapy]], and [[chemotherapy]] are often the treatment of choice for hemangioendothelioma. | ||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 15: | Line 15: | ||
==Classification== | ==Classification== | ||
*Hemangioendothelioma may be classified into 4 groups: | *Hemangioendothelioma may be classified into 4 groups: | ||
:*Epithelioid hemangioendothelioma | :*Epithelioid hemangioendothelioma (most common) | ||
:* | :*Kaposiform hemangioendothelioma | ||
:*Retiform hemangioendothelioma | :*Retiform hemangioendothelioma | ||
:*[[Infantile hemangioendothelioma]] | :*[[Infantile hemangioendothelioma]] | ||
| Line 33: | Line 33: | ||
*On gross pathology, characteristic findings of hemangioendothelioma, include: | *On gross pathology, characteristic findings of hemangioendothelioma, include: | ||
:*No hallmark features | :*No hallmark features | ||
:*Size may range up to 18 cm | :*Size may range up to 18 cm | ||
*On microscopic histopathological analysis, characteristic findings of hemangioendothelioma, include: | *On microscopic histopathological analysis, characteristic findings of hemangioendothelioma, include: | ||
:*Large epithelioid perivascular cells | :*Large epithelioid perivascular cells | ||
| Line 40: | Line 40: | ||
:*May form lumen and have red blood cells within | :*May form lumen and have red blood cells within | ||
:*Vesicular nucleus with prominent nucleolus in some cells | :*Vesicular nucleus with prominent nucleolus in some cells | ||
:*Tuft-like projections into capillaries | :*Tuft-like projections into capillaries | ||
'''Papillary intralymphatic hemangioendothelioma''' | '''Papillary intralymphatic hemangioendothelioma''' | ||
:*Papillary tufts | :*Papillary tufts | ||
| Line 88: | Line 88: | ||
== Natural History, Complications and Prognosis== | == Natural History, Complications and Prognosis== | ||
*The majority of patients with hemangioendothelioma are symptomatic at the time of diagnosis.<ref name="pmid3303234">{{cite journal |vauthors=Weiss SW, Ishak KG, Dail DH, Sweet DE, Enzinger FM |title=Epithelioid hemangioendothelioma and related lesions |journal=Semin Diagn Pathol |volume=3 |issue=4 |pages=259–87 |year=1986 |pmid=3303234 |doi= |url=}}</ref> | *The majority of patients with hemangioendothelioma are symptomatic at the time of diagnosis.<ref name="pmid3303234">{{cite journal |vauthors=Weiss SW, Ishak KG, Dail DH, Sweet DE, Enzinger FM |title=Epithelioid hemangioendothelioma and related lesions |journal=Semin Diagn Pathol |volume=3 |issue=4 |pages=259–87 |year=1986 |pmid=3303234 |doi= |url=}}</ref> | ||
*Early clinical features of hemangioendothelioma are often unspecific (eg. | *Early clinical features of hemangioendothelioma are often unspecific (eg. abdominal pain, mass, weight loss, or fatigue). | ||
*If left untreated, the majority of patients with hemangioendothelioma may progress to develop metastases. | *If left untreated, the majority of patients with hemangioendothelioma may progress to develop metastases. | ||
*Common complications of hemangioendothelioma, include: | *Common complications of hemangioendothelioma, include: | ||
Revision as of 20:47, 22 April 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Synonyms and keywords: Infantile hemangioendothelioma; Kaposiform hemangioendothelioma; Retiform hemangioendothelioma; Epithelioid hemangioendothelioma; Dabska tumor
Overview
Hemangioendotheliomas is a rare group of mesenchymal vascular neoplasms. Hemangioendotheliomas commonly present with an enlarging mass and have been reported in the head and neck, lungs, lymph nodes, pleura, retroperitoneum, or stomach. Hemangioendotheliomas may be benign or malignant, and tend to occur around medium to large venous structures. Hemangioendothelioma may be classified into 4 groups: epitheloid hemangioendothelioma (most common), kaposiform hemangioendothelioma, retiform hemangioendothelioma, and infantile hemangioendothelioma. The prevalence of hemangioendothelioma is approximately 1 per 100,000 individuals worldwide. The majority of patients with hemangioendothelioma are symptomatic at the time of diagnosis.[1] Early clinical features of hemangioendothelioma are often unspecific, such as: abdominal pain, mass, weight loss, or fatigue. On CT, characteristic findings of hepatic hemangioendothelioma, may include: multiple hypo-attenuating lesions in both hepatic lobes, coalesce to form larger confluent hypo-attenuating regions in a peripheral or subcapsular distribution, halo or target pattern of enhancement in larger lesions, subcapsular lesion (with capsular retraction), and located in a predominantly peripheral. Surgical resection, radiotherapy, and chemotherapy are often the treatment of choice for hemangioendothelioma.
Historical Perspective
- Hemangioendothelioma was first described by Sharon Weiss, an American pathologist, in 1986.
Classification
- Hemangioendothelioma may be classified into 4 groups:
- Epithelioid hemangioendothelioma (most common)
- Kaposiform hemangioendothelioma
- Retiform hemangioendothelioma
- Infantile hemangioendothelioma
- Type I
- Multiple vascular channels
- Formed by an immature endothelial lining
- Stromal separation from bile ductules
- Type II:
- Disorganized appearance and hypercellular
- There are no bile ductules
Pathophysiology
- The pathogenesis of hemangioendothelioma is characterized by epithelioid-like features.
- Hemangioendotheliomas tend to occur around medium to large venous structures.
- There are no genetic mutations associated with the development of hemangioendothelioma.
- On gross pathology, characteristic findings of hemangioendothelioma, include:
- No hallmark features
- Size may range up to 18 cm
- On microscopic histopathological analysis, characteristic findings of hemangioendothelioma, include:
- Large epithelioid perivascular cells
- Abundant pale eosinophilic cytoplasm
- Cytoplasmic vacuolation (some cells) (also known as "blister cells") - key feature.
- May form lumen and have red blood cells within
- Vesicular nucleus with prominent nucleolus in some cells
- Tuft-like projections into capillaries
Papillary intralymphatic hemangioendothelioma
- Papillary tufts
- Central hyaline core lined by hobnail-like endothelial cells protruding into the lumina
Retiform hemangioendothelioma
- Infiltrative neoplasm composed of elongated arborizing vessels
- Arranged in an anastomosing pattern
- Lined by a single layer of "hobnail-like" endothelial cells (protrude within the narrow lumina)
Kaposiform hemangioendothelioma
- Composed of several solid poorly circumscribed nodules
- Nodules composed of a mixture of small capillaries and solid lobules
- Arranged in a glomeruloid pattern
- On immunohistochemistry, characteristic findings of hemangioendothelioma, include:
- Positive CD31
- Positive CD34
- Positive Factor VIII
Causes
- There are no established causes for hemangioendothelioma.
Differentiating Hemangioendothelioma from Other Diseases
- Hemangioendothelioma must be differentiated from other diseases that cause a hypervascular mass, or abdominal pain, such as:
- Hepatoblastoma
- Hemangioma
- Angiosarcoma
- Colangiocarcinoma
Epidemiology and Demographics
- The prevalence of hemangioendothelioma is approximately 1 per 100,000 individuals worldwide.
- Hemangioendothelioma is very rare.
Age
- Patients of all age groups may develop hemangioendothelioma.
Gender
- Hemangioendothelioma affects men and women equally.
Race
- There is no racial predilection for hemangioendothelioma.
Risk Factors
- Common risk factors in the development of hemangioendothelioma, include:
- Oral contraceptives
- Polyvinyl chloride
Natural History, Complications and Prognosis
- The majority of patients with hemangioendothelioma are symptomatic at the time of diagnosis.[1]
- Early clinical features of hemangioendothelioma are often unspecific (eg. abdominal pain, mass, weight loss, or fatigue).
- If left untreated, the majority of patients with hemangioendothelioma may progress to develop metastases.
- Common complications of hemangioendothelioma, include:
- Hepatic failure
- Multi-organ failure
- Cardiac failure
- Prognosis is generally poor, and the 5-year survival rate of patients with hemangioendothelioma is approximately 55%
Diagnosis
Symptoms
- Hemangioendothelioma is usually asymptomatic.
- Symptoms of hemangioendothelioma may include the following:
- Abdominal pain
- Fatigue
Physical Examination
- Patients with hemangioendothelioma usually may be well-appearing.
- Physical examination may be remarkable for:
Palpation
- Abdominal large mass
- Hepatomegaly
Laboratory Findings
- There are no specific laboratory findings associated with hemangioendothelioma.
Imaging Findings
- On CT, characteristic findings of hemangioendothelioma, include:
Hepatic Hemangioendothelioma
- Multiple hypo-attenuating lesions in both hepatic lobes
- That coalesce to form larger confluent hypo-attenuating regions in a peripheral or subcapsular distribution
- Halo or target pattern of enhancement in larger lesions
- Subcapsular lesion often present with capsular retraction
- Located in a predominantly peripheral distribution, with coalescence as individual nodules.
- Honeycomb appearance
- On MRI, characteristic findings of hemangioendothelioma, include:
Hepatic Hemangioendothelioma
- T1: hypointense lesions relative to normal liver parenchyma on unenhanced T1-weighted images
- T2: heterogeneously increased signal intensity
- C+ (Gd): some lesions demonstrate either a peripheral halo or a target-type enhancement pattern after administration of a gadolinium-based contrast agent, with occasional observation of a thin peripheral hypointense rim
Treatment
Medical Therapy
- There is no treatment for hemangioendothelioma; the mainstay of therapy is supportive care.
- Common therapies for hemangioendothelioma, may include:
- Interferon
- Sorafenib (kinase inhibitor)
- Corticosteroids
- Paclitaxel
- Thalidomide
- Doxorubicin
- Radiation therapy for hemangioendothelioma remains unclear.
Surgery
- Surgery is the mainstay of therapy for hemangioendothelioma.
- The recurrence rate after surgery of hemangioendothelioma is approximately 40%.
- Infantile hepatic hemangioendothelioma has a good prognosis.
Prevention
- There are no primary preventive measures available for hemangioendothelioma.